Party Drugs — The Global Picture and an Harm Reduction Overview

[smfadmin (OP)]

Party Drugs — A Global View and an Harm Reduction Overview

Australia, the United States and the United Kingdom — who uses them, how many, what the risks actually are, and what the system gets wrong.


The Global Numbers

Around 40-50% of adults in Western countries have tried an illicit drug at least once, with cannabis accounting for the majority of that figure. For party drugs specifically — MDMA, cocaine, stimulants and novel psychoactive substances — lifetime experimentation sits at roughly 10-20% across Australia, the United States and the United Kingdom.

The majority of people who try party drugs do so a handful of times and move on. Those who don't are usually carrying pre-existing vulnerability that the substance is meeting rather than creating. Shame-based prevention ignores this distinction entirely and is therefore largely ineffective across all three countries.

Regional differences worth knowing:

• Australia: ranks among the highest per capita consumers of MDMA and cocaine globally. Wastewater analysis confirms substantial use well above what self-report surveys capture. Methamphetamine has shifted from urban nightlife toward regional communities over the past decade
  
  
• United States: methamphetamine use is far more widespread geographically than in Australia or the UK — particularly in rural and midwest communities — driven by domestic production history and now the fentanyl-contaminated supply. The opioid crisis has reshaped the entire drug landscape, with many people entering problematic stimulant use via prescription opioid pathways
  
  
• United Kingdom: MDMA and cocaine dominate the party drug market. The UK has some of the highest MDMA potency in the world — pills in circulation frequently contain 200mg or more, far above what many users expect. Ketamine use is also significantly higher in the UK party scene than in Australia or the US
  

MDMA

MDMA is one of the most widely used party drugs across all three countries, concentrated in nightlife, festival and rave culture. Lifetime use sits at approximately 10-12% of adults in Australia and the UK, with somewhat lower figures in the US.

What it does: Releases serotonin, dopamine and noradrenaline simultaneously, producing euphoria, empathy, emotional openness and mild stimulation. Duration 3-5 hours.

Regional note: UK pill potency is a particular concern — pills routinely tested at 200-300mg in recent years, compared to the 80-120mg that was common a decade ago. A dose that felt manageable previously may now be double or triple what the user expects. Testing is not optional in the UK market.

Key risks:

• Hyperthermia: the leading cause of MDMA-related death across all three countries — dancing in hot environments without adequate hydration drives body temperature to dangerous levels
  
• Hyponatremia: the opposite problem — overdrinking water without electrolytes causes sodium dilution, also potentially fatal. More common in female users due to physiological differences in fluid retention
  
• Adulteration: pills sold as MDMA frequently contain other substances. Fentanyl contamination has been detected in samples across Australia and the US. NBOMe compounds have appeared in UK supplies. Drug checking services save lives
  
• Serotonin syndrome: dangerous and potentially fatal interaction with SSRIs, MAOIs, lithium and other serotonergic drugs — a risk that is dramatically underreported given how many people take antidepressants
  
• Neurotoxicity: heavy or frequent use is associated with serotonergic damage — cognitive effects including memory impairment have been documented in heavy users. The brain needs time to recover between uses
  
• Comedown: serotonin depletion produces low mood, fatigue and anxiety for 1-3 days post use — sometimes called "suicide Tuesday" in UK and Australian slang
  

Harm reduction: Test your substances — reagent test kits are widely available in all three countries. Stay cool. Drink 500ml of water per hour if dancing, less if not. Avoid mixing with any serotonergic medication. Space use by at least 3 months to allow serotonergic recovery.


Cocaine

Cocaine use is substantial and growing across all three countries, though the demographic and cultural profile differs.

Australia ranks among the highest per capita cocaine consuming nations globally. The UK has seen dramatic increases in use over the past decade, with purity rising and prices falling. The US market is large in absolute terms but cocaine's profile there has been overshadowed by the opioid crisis — though use remains significant particularly in urban centres.

What it does: Blocks reuptake of dopamine, serotonin and noradrenaline, producing intense but short-lived euphoria, confidence and stimulation. Duration 20-40 minutes — which drives compulsive redosing.

The social acceptability problem: In all three countries, cocaine's primary user demographic skews urban, professional and higher income. This confers a social acceptability that methamphetamine never enjoyed, despite comparable legal status and overlapping cardiovascular risks. Nobody declares a cocaine crisis. The harm is real regardless.

Key risks:

• Cardiovascular: cocaine is the leading cause of drug-related cardiac events across all three countries — acute coronary events, arrhythmia and hypertension, all amplified by exertion and alcohol
  
• Cocaethylene: when cocaine and alcohol are combined — as they almost universally are in social settings — the liver produces cocaethylene, which is more cardiotoxic than either substance alone and has a longer half-life. This is the most underappreciated risk in the cocaine-using population
  
• Levamisole: a veterinary anthelmintic used as a cutting agent, present in the majority of cocaine supplies across all three countries. Linked to agranulocytosis — serious and potentially fatal immune cell suppression in regular users
  
• Compulsive redosing: the short duration of effect is cocaine's most underestimated harm. Casual social use escalates faster than users expect
  
• Nasal damage: chronic insufflation causes septal perforation and nasal passage destruction — entirely preventable with basic harm reduction practice
  
• Crack cocaine — US and UK: freebase cocaine smoked as crack carries significantly higher addiction potential and harm profile than powder cocaine due to ROA and speed of onset. Crack use in the US and UK is substantially higher than in Australia and carries its own distinct harm reduction considerations
  
• Psychological: paranoia, anxiety and aggression with heavy use, particularly combined with sleep deprivation and alcohol
  

Harm reduction: Avoid combining with alcohol — this is the single most impactful harm reduction step for cocaine users. Test for levamisole. Rest the nasal passages — alternate nostrils, rinse with saline. Know that the short duration is a trap, not a feature. If using crack, pipe sharing carries significant infection risk.


Stimulants — Amphetamine and Methamphetamine

The stimulant landscape differs significantly across the three countries and is worth understanding in regional context.

Australia: Methamphetamine dominated urban party markets through the 2000s and 2010s. The market has shifted — meth has moved toward regional communities while cocaine has taken its place in city nightlife. Ice (crystal methamphetamine) remains the primary form.

United States: Methamphetamine is a national crisis in a way that has no parallel in Australia or the UK. Use is geographically widespread — rural midwest, southwest, west coast — and the supply has shifted from domestic production to Mexican cartel imports of extraordinarily pure product. Fentanyl contamination of the meth supply is now documented and represents an emerging mortality risk. Approximately 15-20% of those who try methamphetamine develop dependence.

United Kingdom: Amphetamine sulphate (speed) has historically been more common than methamphetamine in the UK party scene. Crystal meth use exists but is concentrated in specific communities — particularly the chemsex scene — rather than mainstream nightlife.

What it does: Releases dopamine, noradrenaline and serotonin — more potently and durably than cocaine. Duration 8-12 hours depending on ROA. Route of administration dramatically affects both effect and risk profile.

Key risks:

• Cardiovascular: hypertension, tachycardia, arrhythmia — amplified by exertion
  
• Psychosis: stimulant psychosis can emerge with heavy or prolonged use and may persist beyond cessation. Risk is higher with methamphetamine than amphetamine sulphate
  
• Dependence: approximately 15-20% of those who try methamphetamine develop dependence — significantly higher than MDMA or cocaine, driven substantially by ROA
  
• Neurotoxicity: heavy use is associated with dopaminergic and serotonergic damage. Recovery is possible but takes time
  
• Sleep deprivation: extended wakefulness compounds all other risks significantly
  
• ROA risk: smoking and IV use dramatically increase both addiction potential and physical harm compared to oral use. The rush from smoking or IV is the primary driver of the compulsive use pattern
  
• Fentanyl contamination — US: confirmed in methamphetamine supplies in multiple US states. Users who believe they are using only meth may be exposed to opioid overdose risk without knowing it. Fentanyl test strips are essential
  

Harm reduction: Oral ROA carries significantly lower risk than smoking or IV. Sleep. Eat. The recovery period is manageable with food, water, rest and time. There is no pharmacological shortcut — the brain needs time. In the US specifically: test your supply for fentanyl.


Synthetic Cathinones — Bath Salts

Synthetic cathinones are stimulant compounds derived from cathinone, the active constituent of the khat plant. Marketed variously as "bath salts," "plant food" or "research chemicals," they were designed to mimic the effects of MDMA, cocaine and amphetamines while evading drug laws. The name "bath salts" is a marketing fiction — these substances have nothing to do with bathing products.

Prevalence: Synthetic cathinones had their peak in the US and UK between approximately 2010-2015, driven by legal grey area status. Scheduling has reduced but not eliminated their availability. They remain present in all three countries, often misrepresented as MDMA or other substances.

Common compounds: Mephedrone (4-MMC), MDPV, methylone, alpha-PVP (flakka or α-PVP) and hundreds of variants. Each has a distinct pharmacological profile — generalising across all cathinones is not possible.

What they do: Most synthetic cathinones primarily block reuptake or stimulate release of dopamine, noradrenaline and serotonin in varying ratios. Effects can resemble MDMA, cocaine or amphetamine depending on the specific compound. Duration varies widely.

Key risks:

• Extreme variability: potency and effect profile vary dramatically between compounds and even between batches of the same compound. What worked at one dose previously may be dangerous at the same dose with a different product
  
• Cardiovascular: tachycardia, hypertension and cardiac events documented across multiple cathinone compounds
  
• Psychosis and agitation: synthetic cathinones — particularly MDPV and alpha-PVP — are associated with severe agitation, paranoia and psychosis at higher doses. The "bath salts" media stories of extreme behaviour have some basis in reality with specific high-dopaminergic compounds
  
• Hyperthermia: temperature dysregulation documented, particularly with MDPV
  
• Compulsive redosing: particularly pronounced with MDPV and alpha-PVP due to short duration and intense dopaminergic effect — sometimes described as among the most compulsive substances known
  
• Unknown compounds: the NPS market moves faster than any testing regime. A substance sold as mephedrone today may be a different cathinone entirely
  

Harm reduction: Test everything — reagent testing can identify cathinone class but not specific compounds. Start with an extremely small test dose and wait. Do not redose compulsively. Avoid combining with other stimulants or alcohol. If psychosis or extreme agitation develops, this is a medical emergency.


Novel Psychoactive Substances (NPS) — Beyond Cathinones

NPS represent the most rapidly evolving and least understood category of party drugs. New compounds appear faster than regulation or research can track across all three countries.

Common categories:

• NBOMe compounds: sold as LSD substitutes across all three countries — significantly more dangerous, with a narrow margin between active and toxic dose. Deaths documented in Australia, US and UK
  
• Synthetic cannabinoids (Spice/K2): bear little pharmacological resemblance to cannabis despite the marketing. Associated with seizures, psychosis, cardiovascular events and death. Particularly prevalent in UK and US prison populations and among homeless communities where drug testing is a concern
  
• Novel opioids — nitazenes: extraordinarily potent synthetic opioids emerging across all three countries. Poorly reversed by standard naloxone doses — multiple doses required. Represent an escalating mortality risk
  
• Novel benzodiazepines: appear in pill supplies across all three countries, long half-lives, unpredictable potency, significant withdrawal risk with repeated use
  
• Dissociatives: novel ketamine analogues and PCP variants present in all three markets
  

The core problem: No established safety profile. Unknown doses. Common adulteration. Pharmacology frequently poorly understood even by researchers. The legal grey area that created the NPS market has been progressively closed by blanket bans in all three countries — but the compounds keep coming.

Harm reduction: Test everything. Drug checking services operate in all three countries and are not optional with NPS. Never assume a substance is what it is sold as. Minimal test dose first, always. If nitazenes are suspected in an opioid overdose — multiple doses of naloxone and immediate emergency services.


The Inconsistency

Drug law across Australia, the US and the UK does not track harm. MDMA — which has genuine therapeutic potential now recognised by researchers in all three countries — carries severe criminal penalties. Cocaine's social acceptability protects its users from stigma applied to methamphetamine users despite comparable legal status and overlapping risks. Alcohol and tobacco, which cause vastly more population-level harm than all party drugs combined, remain legal and heavily marketed.

Harm reduction follows the drug and the person — not the demographic, not the legal category, and not the stigma attached to the user.


What Actually Reduces Harm

• Test your substances — drug checking services and reagent test kits are available in all three countries. Use them
  
• Know your interactions — particularly alcohol with cocaine, serotonergic drugs with MDMA, and opioids with anything
  
• Start low, go slow — especially with unknown substances or new supply
  
• Stay hydrated but not over-hydrated — 500ml per hour if dancing, less if not
  
• Sleep and eat — before, during where possible, and after
  
• Have people around you who know what you have taken
  
• US users specifically: carry fentanyl test strips and naloxone — the contaminated supply makes this essential regardless of what substance you believe you are using
  
• Remove shame from the equation — shame prevents help-seeking and kills people across all three countries equally
  

Most people who use party drugs do so a handful of times and move on without lasting harm. The minority who don't are usually carrying something the drug is meeting rather than something the drug created. Understanding that distinction is where genuine harm reduction begins — in Australia, the United States, the United Kingdom, and everywhere else.

[Chip]

Reddit uses Markdown:

The reddit post:

Code: [Select]

# Party Drugs — A Global Harm Reduction Overview

*Australia, the United States and the United Kingdom — who uses them, how many, what the risks actually are, and what the system gets wrong.*

---

## The Global Numbers

Around 40–50% of adults in Western countries have tried an illicit drug at least once, with cannabis accounting for the majority of that figure. For party drugs specifically—MDMA, cocaine, stimulants and novel psychoactive substances—lifetime experimentation sits at roughly 10–20% across Australia, the United States and the United Kingdom.

The majority of people who try party drugs do so a handful of times and move on. Those who don't are usually carrying pre-existing vulnerability that the substance is meeting rather than creating. Shame-based prevention ignores this distinction entirely and is therefore largely ineffective across all three countries.

**Regional differences worth knowing:**

- **Australia:** Ranks among the highest per capita consumers of MDMA and cocaine globally. Wastewater analysis confirms substantial use well above what self-report surveys capture. Methamphetamine has shifted from urban nightlife toward regional communities over the past decade.

- **United States:** Methamphetamine use is far more widespread geographically than in Australia or the UK—particularly in rural and Midwest communities—driven by domestic production history and now the fentanyl-contaminated supply. The opioid crisis has reshaped the entire drug landscape.

- **United Kingdom:** MDMA and cocaine dominate the party drug market. The UK has some of the highest MDMA potency in the world, with pills frequently containing 200 mg or more—far above what many users expect. Ketamine use is also significantly higher in the UK party scene.

---

My full article can be found here:

https://forum.drugs-and-users.org/index.php?topic=7525.msg49233#msg49233

The full version:

Code: [Select]

---

# Party Drugs — A Global Harm Reduction Overview
*Australia, the United States and the United Kingdom — who uses them, how many, what the risks actually are, and what the system gets wrong.*

---

## The Global Numbers

Around 40-50% of adults in Western countries have tried an illicit drug at least once, with cannabis accounting for the majority of that figure. For party drugs specifically — MDMA, cocaine, stimulants and novel psychoactive substances — lifetime experimentation sits at roughly 10-20% across Australia, the United States and the United Kingdom.

The majority of people who try party drugs do so a handful of times and move on. Those who don't are usually carrying pre-existing vulnerability that the substance is meeting rather than creating. Shame-based prevention ignores this distinction entirely and is therefore largely ineffective across all three countries.

**Regional differences worth knowing:**

- **Australia:** ranks among the highest per capita consumers of MDMA and cocaine globally. Wastewater analysis confirms substantial use well above what self-report surveys capture. Methamphetamine has shifted from urban nightlife toward regional communities over the past decade
- **United States:** methamphetamine use is far more widespread geographically than in Australia or the UK — particularly in rural and midwest communities — driven by domestic production history and now the fentanyl-contaminated supply. The opioid crisis has reshaped the entire drug landscape
- **United Kingdom:** MDMA and cocaine dominate the party drug market. The UK has some of the highest MDMA potency in the world — pills in circulation frequently contain 200mg or more, far above what many users expect. Ketamine use is also significantly higher in the UK party scene

---

## MDMA

MDMA is one of the most widely used party drugs across all three countries, concentrated in nightlife, festival and rave culture. Lifetime use sits at approximately 10-12% of adults in Australia and the UK, with somewhat lower figures in the US.

**What it does:** Releases serotonin, dopamine and noradrenaline simultaneously, producing euphoria, empathy, emotional openness and mild stimulation. Duration 3-5 hours.

**Regional note:** UK pill potency is a particular concern — pills routinely tested at 200-300mg in recent years. A dose that felt manageable previously may now be double or triple what the user expects. Testing is not optional in the UK market.

**Key risks:**

- **Hyperthermia:** the leading cause of MDMA-related death across all three countries — dancing in hot environments without adequate hydration drives body temperature to dangerous levels
- **Hyponatremia:** overdrinking water without electrolytes causes sodium dilution, also potentially fatal. More common in female users
- **Adulteration:** pills sold as MDMA frequently contain other substances. Fentanyl contamination detected in Australian and US samples. NBOMe compounds have appeared in UK supplies
- **Serotonin syndrome:** dangerous interaction with SSRIs, MAOIs, lithium and other serotonergic drugs — a risk dramatically underreported given how many people take antidepressants
- **Neurotoxicity:** heavy or frequent use associated with serotonergic damage. The brain needs time to recover between uses
- **Comedown:** serotonin depletion produces low mood, fatigue and anxiety for 1-3 days — sometimes called "Suicide Tuesday"

**Harm reduction:** Test your substances. Stay cool. Drink 500ml of water per hour if dancing, less if not. Avoid mixing with any serotonergic medication. Space use by at least 3 months.

---

## Cocaine

Cocaine use is substantial and growing across all three countries.

Australia ranks among the highest per capita cocaine consuming nations globally. The UK has seen dramatic increases over the past decade, with purity rising and prices falling. The US market is large in absolute terms but cocaine's profile has been overshadowed by the opioid crisis — though use remains significant particularly in urban centres.

**What it does:** Blocks reuptake of dopamine, serotonin and noradrenaline, producing intense but short-lived euphoria, confidence and stimulation. Duration 20-40 minutes — which drives compulsive redosing.

**The social acceptability problem:** In all three countries, cocaine's primary user demographic skews urban, professional and higher income. This confers a social acceptability that methamphetamine never enjoyed, despite comparable legal status and overlapping cardiovascular risks. Nobody declares a cocaine crisis. The harm is real regardless.

**Key risks:**

- **Cardiovascular:** cocaine is the leading cause of drug-related cardiac events across all three countries — acute coronary events, arrhythmia and hypertension, amplified by exertion and alcohol
- **Cocaethylene:** when cocaine and alcohol are combined the liver produces cocaethylene — more cardiotoxic than either substance alone, with a longer half-life. Near-universal among social users who drink and use simultaneously. The most underappreciated risk in the cocaine-using population
- **Levamisole:** present in the majority of cocaine supplies across all three countries. Linked to agranulocytosis — serious immune cell suppression in regular users
- **Compulsive redosing:** the short duration of effect is cocaine's most underestimated harm
- **Nasal damage:** chronic insufflation causes septal perforation — entirely preventable
- **Crack cocaine — US and UK:** freebase cocaine smoked as crack carries significantly higher addiction potential due to ROA and speed of onset. Crack use in the US and UK is substantially higher than in Australia
- **Psychological:** paranoia, anxiety and aggression with heavy use, particularly combined with sleep deprivation

**Harm reduction:** Avoid combining with alcohol — the single most impactful harm reduction step for cocaine users. Test for levamisole. Alternate nostrils, rinse with saline. Know that the short duration is a trap, not a feature.

---

## Stimulants — Amphetamine and Methamphetamine

The stimulant landscape differs significantly across the three countries.

**Australia:** Meth dominated urban party markets through the 2000s and 2010s before shifting toward regional communities. Cocaine has taken its place in city nightlife.

**United States:** Methamphetamine is a national crisis with no parallel in Australia or the UK. Use is geographically widespread — rural midwest, southwest, west coast. The supply has shifted from domestic production to Mexican cartel imports of extraordinarily pure product. Fentanyl contamination of the meth supply is now documented and represents an emerging mortality risk.

**United Kingdom:** Amphetamine sulphate (speed) has historically been more common than methamphetamine. Crystal meth use exists but is concentrated in specific communities — particularly the chemsex scene.

**What it does:** Releases dopamine, noradrenaline and serotonin more potently and durably than cocaine. Duration 8-12 hours depending on ROA.

**Key risks:**

- **Cardiovascular:** hypertension, tachycardia, arrhythmia — amplified by exertion
- **Psychosis:** can emerge with heavy or prolonged use and may persist beyond cessation
- **Dependence:** approximately 15-20% of those who try methamphetamine develop dependence — significantly higher than MDMA or cocaine, driven substantially by ROA
- **Neurotoxicity:** heavy use associated with dopaminergic and serotonergic damage. Recovery is possible but takes time
- **Sleep deprivation:** extended wakefulness compounds all other risks significantly
- **ROA risk:** smoking and IV use dramatically increase addiction potential and physical harm compared to oral use
- **Fentanyl contamination — US:** confirmed in methamphetamine supplies in multiple states. Fentanyl test strips are essential

**Harm reduction:** Oral ROA carries significantly lower risk than smoking or IV. Sleep. Eat. There is no pharmacological shortcut — the brain needs time. US users: test your supply for fentanyl.

---

## Synthetic Cathinones — Bath Salts

Synthetic cathinones are stimulant compounds derived from cathinone, the active constituent of the khat plant. Marketed as "bath salts," "plant food" or "research chemicals," they were designed to mimic MDMA, cocaine and amphetamines while evading drug laws. The name is a marketing fiction.

**Prevalence:** Peak use in the US and UK between 2010-2015. Scheduling has reduced but not eliminated availability. Remain present in all three countries, often misrepresented as MDMA or other substances.

**Common compounds:** Mephedrone (4-MMC), MDPV, methylone, alpha-PVP (flakka or α-PVP) and hundreds of variants. Each has a distinct pharmacological profile.

**Key risks:**

- **Extreme variability:** potency and effect profile vary dramatically between compounds and batches
- **Cardiovascular:** tachycardia, hypertension and cardiac events documented
- **Psychosis and agitation:** particularly with MDPV and alpha-PVP — the "bath salts" media stories of extreme behaviour have some basis in reality with specific high-dopaminergic compounds
- **Hyperthermia:** temperature dysregulation documented, particularly with MDPV
- **Compulsive redosing:** particularly pronounced with MDPV and alpha-PVP — among the most compulsive substances known
- **Unknown compounds:** the NPS market moves faster than any testing regime

**Harm reduction:** Test everything. Extremely small test dose first. Do not redose compulsively. Avoid combining with other stimulants or alcohol. Severe agitation or psychosis is a medical emergency.

---

## Novel Psychoactive Substances (NPS)

NPS represent the most rapidly evolving and least understood category of party drugs. New compounds appear faster than regulation or research can track.

**Common categories:**

- **NBOMe compounds:** sold as LSD substitutes — significantly more dangerous, narrow margin between active and toxic dose. Deaths documented in Australia, US and UK
- **Synthetic cannabinoids (Spice/K2):** bear little pharmacological resemblance to cannabis. Associated with seizures, psychosis, cardiovascular events and death. Particularly prevalent in UK and US prison populations
- **Novel opioids — nitazenes:** extraordinarily potent. Poorly reversed by standard naloxone doses — multiple doses required. Escalating mortality risk across all three countries
- **Novel benzodiazepines:** long half-lives, unpredictable potency, significant withdrawal risk
- **Dissociatives:** novel ketamine analogues and PCP variants present in all three markets

**Harm reduction:** Test everything. Drug checking services operate in all three countries. Minimal test dose first, always. Suspected nitazene overdose — multiple doses of naloxone and immediate emergency services.

---

## The Inconsistency

Drug law across Australia, the US and the UK does not track harm. MDMA — which has genuine therapeutic potential now recognised by researchers in all three countries — carries severe criminal penalties. Cocaine's social acceptability protects its users from stigma applied to methamphetamine users despite comparable legal status. Alcohol and tobacco, which cause vastly more population-level harm than all party drugs combined, remain legal and heavily marketed.

Harm reduction follows the drug and the person — not the demographic, not the legal category, and not the stigma attached to the user.

---

## What Actually Reduces Harm

- **Test your substances** — drug checking services and reagent test kits are available in all three countries. Use them
- **Know your interactions** — particularly alcohol with cocaine, serotonergic drugs with MDMA, and opioids with anything
- **Start low, go slow** — especially with unknown substances or new supply
- **Stay hydrated but not over-hydrated** — 500ml per hour if dancing, less if not
- **Sleep and eat** — before, during where possible, and after
- **Have people around you who know what you have taken**
- **US users specifically:** carry fentanyl test strips and naloxone — the contaminated supply makes this essential regardless of what substance you believe you are using
- **Remove shame from the equation** — shame prevents help-seeking and kills people across all three countries equally

---

*Most people who use party drugs do so a handful of times and move on without lasting harm. The minority who don't are usually carrying something the drug is meeting rather than something the drug created. Understanding that distinction is where genuine harm reduction begins — in Australia, the United States, the United Kingdom, and everywhere else.*

*— drugs-and-users.org*

---